版本:
中国

BRIEF-U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's humira

March 30 Abbvie Inc:

* U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's Humira (adalimumab) prescribing information

* U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's Humira (adalimumab) prescribing information

* Abbvie Inc - phase 3 data demonstrate improvement in moderate to severe fingernail psoriasis Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐